Summary
0.42 -0.00(-0.21%)05/16/2024
Trevena Inc (TRVN)
Trevena Inc (TRVN)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
2.34 | 6.18 | 2.34 | -26.79 | -27.28 | -86.34 | -71.50 | -93.47 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 0.42 | |
Open | 0.44 | |
High | 0.45 | |
Low | 0.40 | |
Volume | 109,401 | |
Change | 0.01 | |
Change % | 2.34 | |
Avg Volume (20 Days) | 177,107 | |
Volume/Avg Volume (20 Days) Ratio | 0.62 | |
52 Week Range | 0.30 - 3.28 | |
Price vs 52 Week High | -87.05% | |
Price vs 52 Week Low | 41.57% | |
Range | -3.48 | |
Gap Up/Down | -0.01 |
Fundamentals | ||
Market Capitalization (Mln) | 8 | |
EBIDTA | -34,954,000 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 6.00 | |
Book Value | -0.4430 | |
Earnings Per Share | -3.1600 | |
EPS Estimate Current Quarter | -0.1500 | |
EPS Estimate Next Quarter | -0.1500 | |
EPS Estimate Current Year | -1.7200 | |
EPS Estimate Next Year | -1.3500 | |
Diluted EPS (TTM) | -3.1600 | |
Revenues | ||
Profit Marging | 0.0000 | |
Operating Marging (TTM) | 123.7439 | |
Return on asset (TTM) | -0.4940 | |
Return on equity (TTM) | -10.1458 | |
Revenue TTM | 3,125,000 | |
Revenue per share TTM | 0.2450 | |
Quarterly Revenue Growth (YOY) | -0.7000 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | -3,436,000 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 0.3564 | |
Revenue Enterprise Value | 3.2824 | |
EBITDA Enterprise Value | -0.2850 | |
Shares | ||
Shares Outstanding | 18,321,000 | |
Shares Float | 18,104,456 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.01 | |
Insider (%) | 0.92 | |
Institutions (%) | 7.95 |
05/15 07:00 EST - globenewswire.com
Trevena Reports First Quarter 2024 Results and Provides Business Update
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile
Trevena Reports First Quarter 2024 Results and Provides Business Update
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile
04/01 07:00 EST - globenewswire.com
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies
12/28 14:00 EST - globenewswire.com
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share (or pre-funded warrant in lieu thereof) and associated warrant in a private placement, for gross proceeds to the Company of approximately $1.946 million (the “private placement”).
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share (or pre-funded warrant in lieu thereof) and associated warrant in a private placement, for gross proceeds to the Company of approximately $1.946 million (the “private placement”).
12/27 09:10 EST - globenewswire.com
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share (or pre-funded warrant in lieu thereof) and associated warrant in a private placement, for expected gross proceeds to the Company of approximately $1.946 million (the “private placement”).
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share (or pre-funded warrant in lieu thereof) and associated warrant in a private placement, for expected gross proceeds to the Company of approximately $1.946 million (the “private placement”).
12/04 07:02 EST - globenewswire.com
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner
12/04 07:00 EST - globenewswire.com
Trevena Awarded OLINVYK Agreement with Premier, Inc.
CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, has been awarded a national group purchasing agreement for OLINVYK with Premier, Inc. Effective December 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for OLINVYK.
Trevena Awarded OLINVYK Agreement with Premier, Inc.
CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, has been awarded a national group purchasing agreement for OLINVYK with Premier, Inc. Effective December 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for OLINVYK.
11/30 07:00 EST - globenewswire.com
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
Results from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Meeting in Chicago from April 9th-12th Results from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Meeting in Chicago from April 9th-12th
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
Results from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Meeting in Chicago from April 9th-12th Results from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Meeting in Chicago from April 9th-12th
11/14 09:21 EST - seekingalpha.com
Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript
Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript
Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript
Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript
11/14 07:00 EST - globenewswire.com
Trevena Reports Third Quarter 2023 Results and Provides Business Update
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement
Trevena Reports Third Quarter 2023 Results and Provides Business Update
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement
11/09 07:00 EST - globenewswire.com
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023.
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023.
10/16 07:00 EST - globenewswire.com
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies
TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia, bradycardia, or change in blood pressure reported CHESTERBROOK, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported topline safety and tolerability data for the two Phase 1 proof-of-concept (POC) studies of TRV045, a novel sphingosine-1 phosphate receptor modulator selective for the S1P receptor subtype 1.
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies
TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia, bradycardia, or change in blood pressure reported CHESTERBROOK, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported topline safety and tolerability data for the two Phase 1 proof-of-concept (POC) studies of TRV045, a novel sphingosine-1 phosphate receptor modulator selective for the S1P receptor subtype 1.
10/02 07:00 EST - globenewswire.com
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into respiratory compromise rates
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into respiratory compromise rates
09/06 07:01 EST - globenewswire.com
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China
09/06 07:00 EST - globenewswire.com
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement
TRV045 Demonstrated Statistically Significant Analgesic Effect in Capsaicin-induced Model of Neuropathic Pain in Target Engagement POC Study
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement
TRV045 Demonstrated Statistically Significant Analgesic Effect in Capsaicin-induced Model of Neuropathic Pain in Target Engagement POC Study
08/14 07:00 EST - globenewswire.com
Trevena Reports Second Quarter 2023 Results and Provides Business Update
Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023
Trevena Reports Second Quarter 2023 Results and Provides Business Update
Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023
07/20 07:00 EST - globenewswire.com
Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors
CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed to the Company's Board of Directors, effective July 18 2023.
Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors
CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed to the Company's Board of Directors, effective July 18 2023.
06/26 07:00 EST - globenewswire.com
Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study
OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV opioids (n=982)
Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study
OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV opioids (n=982)
06/05 09:10 EST - zacks.com
Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), The RealReal (REAL), Trevena (TRVN), ChargePoint (CHPT) and Caterpillar (CAT).
Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), The RealReal (REAL), Trevena (TRVN), ChargePoint (CHPT) and Caterpillar (CAT).
05/31 11:16 EST - pennystocks.com
5 Hot Penny Stocks To Watch With Big News This Week
Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.
5 Hot Penny Stocks To Watch With Big News This Week
Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.
05/31 07:00 EST - globenewswire.com
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
$3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first commercial sale in China CHESTERBROOK, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received a $3 million milestone payment from its partner in China for the Chinese approval of OLINVYK.
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
$3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first commercial sale in China CHESTERBROOK, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received a $3 million milestone payment from its partner in China for the Chinese approval of OLINVYK.